Hims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion

Stock Track04-23 20:51

Hims & Hers Health surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.

The sharp increase appears to be driven by the company's announcement that providers delivering ongoing care to Hims & Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.

The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims & Hers' service offerings and revenue potential in the competitive telehealth sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Mizu112299
·04-23 20:54
Awesome
Reply
Like
Report

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1153254321?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 20:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153254321","market":"us","top_or_hot":-1,"title":"Hims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion","media":"Stock Track","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health</a> surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/99bacb028dfb193db26ef5652291cf11\" tg-width=\"756\" tg-height=\"612\"/></p><p>The sharp increase appears to be driven by the company&#39;s announcement that providers delivering ongoing care to Hims &amp; Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.</p><p>The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims &amp; Hers&#39; service offerings and revenue potential in the competitive telehealth sector.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-23 20:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health</a> surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/99bacb028dfb193db26ef5652291cf11\" tg-width=\"756\" tg-height=\"612\"/></p><p>The sharp increase appears to be driven by the company&#39;s announcement that providers delivering ongoing care to Hims &amp; Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.</p><p>The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims &amp; Hers&#39; service offerings and revenue potential in the competitive telehealth sector.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1153254321","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153254321","pubTimestamp":1776948711,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc. (HIMS) surged 10.13% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.The sharp increase appears to be driven by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Hims&Hers Health因FDA批准的GLP-1治疗扩展而飙升超过6%","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/98c2302d418c762ee5767ebbdac846aa","symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.The sharp increase appears to be driven by the company's announcement that providers delivering ongoing care to Hims & Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims & Hers' service offerings and revenue potential in the competitive telehealth sector.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[{"id":556735999815968,"gmtCreate":1776948883298,"gmtModify":1776948886630,"author":{"id":"4094018271031160","authorId":"4094018271031160","name":"Mizu112299","avatar":"https://community-static.tradeup.com/news/3c8b335a691410eefa9c6630ea886f54","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":12,"crmLevelSwitch":1,"idStr":"4094018271031160","authorIdStr":"4094018271031160"},"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/556735999815968","repostId":1153254321,"repostType":2,"repost":{"id":"1153254321","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1776948711,"share":"https://ttm.financial/m/news/1153254321?lang=en_US&edition=fundamental","pubTime":"2026-04-23 20:51","market":"us","language":"en","title":"Hims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1153254321","media":"Stock Track","summary":"Hims & Hers Health Inc. (HIMS) surged 10.13% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.The sharp increase appears to be driven by the...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health</a> surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/99bacb028dfb193db26ef5652291cf11\" tg-width=\"756\" tg-height=\"612\"/></p><p>The sharp increase appears to be driven by the company&#39;s announcement that providers delivering ongoing care to Hims &amp; Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.</p><p>The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims &amp; Hers&#39; service offerings and revenue potential in the competitive telehealth sector.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Soars over 6% on FDA-Approved GLP-1 Treatment Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-23 20:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/HIMS\">Hims &amp; Hers Health</a> surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/99bacb028dfb193db26ef5652291cf11\" tg-width=\"756\" tg-height=\"612\"/></p><p>The sharp increase appears to be driven by the company&#39;s announcement that providers delivering ongoing care to Hims &amp; Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.</p><p>The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims &amp; Hers&#39; service offerings and revenue potential in the competitive telehealth sector.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153254321","content_text":"Hims & Hers Health surged 6.31% in pre-market trading on Thursday, marking a significant upward movement for the telehealth company.The sharp increase appears to be driven by the company's announcement that providers delivering ongoing care to Hims & Hers customers can now prescribe FDA-approved GLP-1 treatments, with medications fulfilled by independent pharmacies. This expansion into the GLP-1 treatment market represents a strategic move to capitalize on the growing demand for these therapies, which are widely used for weight management and related conditions.The ability to offer FDA-approved GLP-1 medications through its platform could significantly expand Hims & Hers' service offerings and revenue potential in the competitive telehealth sector.","news_type":1,"symbols_score_info":{"HIMS":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":false,"newsSizeData":{"likeSize":7,"commentSize":1,"repostSize":1,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}